| 37.65 1.48 (4.09%) | 07-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 44.62 | 1-year : | 52.12 |
| Resists | First : | 38.2 | Second : | 44.62 |
| Pivot price | 33.81 |
|||
| Supports | First : | 31.16 | Second : | 26.8 |
| MAs | MA(5) : | 36.87 |
MA(20) : | 32.59 |
| MA(100) : | 31.44 |
MA(250) : | 30.16 |
|
| MACD | MACD : | 2 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 89.5 |
D(3) : | 88 |
| RSI | RSI(14): 71.2 |
|||
| 52-week | High : | 39.27 | Low : | 20.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IDYA ] has closed below upper band by 19.3%. Bollinger Bands are 162.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 37.78 - 37.96 | 37.96 - 38.12 |
| Low: | 35.66 - 35.87 | 35.87 - 36.05 |
| Close: | 37.33 - 37.66 | 37.66 - 37.95 |
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Fri, 03 Jul 2026
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion - simplywall.st
Sun, 28 Jun 2026
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Fri, 26 Jun 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Thu, 11 Jun 2026
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study - Yahoo Finance
Wed, 10 Jun 2026
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
Mon, 08 Jun 2026
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 8.701e+007 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 11,700 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8068e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -62.2 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 654.6 % |
| Return on Equity (ttm) | -10.8 % |
| Qtrly Rev. Growth | 2.2527e+008 % |
| Gross Profit (p.s.) | -1.1 |
| Sales Per Share | 2.48 |
| EBITDA (p.s.) | -1.79 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -86 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 15.12 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 1.063e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|